Will Production Bottlenecks For BMS’s Abecma Pose Problems After EU Approval?
Abecma has won conditional approval in the EU for certain multiple myeloma patients
Executive Summary
BMS’s pioneering BCMA-directed CAR T-cell immunotherapy has been conditionally approved in the EU to treat certain patients with multiple myeloma, five months after getting the greenlight in the US where high demand for the drug has met production constraints.
You may also be interested in...
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
Medicare And CAR-Ts: Breyanzi Denied Add-On Payments But Tecartus, Abecma Approved
CMS shows willingness to continue approving new technology add-on payments for CAR-T treatments despite suggestions they are no longer needed.
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.